Melanoma

Sanofi-Synthelabo exercises its first option for an antimelanoma vaccine

Published in Vaccine Weekly, April 24th, 2002

Immuno-Designed Molecules, S.A., (IDM) and Sanofi-Synthelabo, S.A., announced that Sanofi-Synthelabo is exercising its first option to develop and market IDM's cell drug known as IDD3 for the treatment of melanoma.

Sanofi-Synthelabo's exercising of their option triggers the payment of milestones, the reimbursement of clinical development costs previously incurred by IDM for this cell drug as well as the reimbursement of the clinical development program as it moves forward.

Following the announcement of their partnership, Sanofi-Synth_labo and IDM agreed that this advanced program is particularly interesting to Sanofi-Synth_labo for the following...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-04-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry